Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

(2017) Jonathan A. Webster et al.   LEUKEMIA RESEARCH

Acute Respiratory Distress Syndrome

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia

(2017) Alessandro Di Tullio et al.   Nature Communications

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer

(2016) David Hong et al.   JOURNAL OF CLINICAL ONCOLOGY

CHK1 as a therapeutic target to bypass chemoresistance in AML

(2016) Laure David et al.   Science Signaling

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia

(2016) Andrea Ghelli Luserna Di Rorà et al.   Oncotarget

Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

(2016) Jianyun Zhao et al.   Oncotarget

CHK1 as a therapeutic target to bypass chemoresistance in AML

(2016) Laure David et al.   Science Signaling

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

(2015) Ilaria Iacobucci et al.   Journal of Hematology & Oncology

Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway

(2015) Marwan Kwok et al.   LANCET

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL+ leukemia cells

(2015) Tri Nguyen et al.   LEUKEMIA RESEARCH

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

(2015) C. King et al.   MOLECULAR CANCER THERAPEUTICS

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970

(2015) Amy B. Hall et al.   Oncotarget

miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis

(2014) R. Norfo et al.   BLOOD

ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses

(2014) R. Josse et al.   CANCER RESEARCH

DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance

(2014) Maria Teresa Esposito et al.   CHROMOSOMA

A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations

(2014) L Zhou et al.   LEUKEMIA

Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia

(2014) Ling Li Yuan et al.   LEUKEMIA RESEARCH

A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function

(2014) Daniel L. Menezes et al.   MOLECULAR CANCER RESEARCH

CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress

(2014) L M Sarmento et al.   ONCOGENE

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo

(2013) L. Chaudhuri et al.   HAEMATOLOGICA

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

(2013) Constance King et al.   INVESTIGATIONAL NEW DRUGS

The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

(2013) Y. Dai et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60)

(2013) Jiřina Vávrová et al.   RADIATION AND ENVIRONMENTAL BIOPHYSICS

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

(2012) Cynthia X. Ma et al.   BREAST CANCER RESEARCH AND TREATMENT

Evaluation of checkpoint kinase targeting therapy in Acute Myeloid Leukemia with complex karyotype

(2012) Christine Didier et al.   CANCER BIOLOGY & THERAPY

Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro

(2012) E. L. Schenk et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

(2012) J. E. Karp et al.   CLINICAL CANCER RESEARCH

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

The clinical relevance of BAALC and ERG expression levels in pediatric AML

(2012) M C H Hermkens et al.   LEUKEMIA

The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells

(2012) H. J. Landau et al.   MOLECULAR CANCER THERAPEUTICS

Model for MLL translocations in therapy-related leukemia involving topoisomerase II -mediated DNA strand breaks and gene proximity

(2012) I. G. Cowell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening

(2011) T. J. Guzi et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites

(2011) R. Montano et al.   MOLECULAR CANCER THERAPEUTICS

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents

(2010) S Zenvirt et al.   ONCOGENE

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

(2009) Carlos Santamaría et al.   ANNALS OF HEMATOLOGY

Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting Therapy

(2009) C. Cavelier et al.   CANCER RESEARCH